Collegium 2025 Q3 Earnings Net Income Surges 237.5% Amid Raised Guidance

Collegium (COLL) reported robust Q3 2025 results, with revenue rising 31.4% to $209.36 million and EPS jumping 244.8% to $1.00. The company raised full-year 2025 guidance for revenue and adjusted EBITDA, reflecting strong demand for its ADHD and pain management portfolios.

Revenue

Earnings/Net Income

Collegium’s EPS surged to $1.00 in Q3 2025 from $0.29 in the prior-year period, while net income expanded 237.5% to $31.51 million. This reflects the company’s improved profitability, driven by strong product demand and operational efficiency. The earnings performance underscores robust financial health and operational success.

Price Action

Post-Earnings Price Action Review

The strategy of buying Collegium shares after its Q3 revenue raise and holding for 30 days demonstrated strong historical performance. Immediate post-earnings gains, such as the 12.20% surge to $40.22 on November 6, 2025, highlighted market optimism. Consistent quarterly revenue raises provided recurring catalysts, while the 30-day hold period mitigated short-term volatility. Long-term fundamentals, including steady revenue growth and profitability, reinforced gains beyond the initial holding period. Positive market sentiment and analyst optimism further supported the stock’s upward trajectory, making the strategy a compelling option for growth-focused investors.

CEO Commentary

Guidance

Collegium raised its 2025 full-year revenue guidance to $775–785 million and adjusted EBITDA to $460–470 million, reflecting confidence in sustained demand for Jornay PM and its pain portfolio. CEO Vikram Karnani emphasized momentum in ADHD therapies and durable pain management sales, while CFO Colleen Tupper highlighted operating margin expansion and disciplined capital deployment.

Additional News

Collegium’s recent acquisition of Ironshore Therapeutics in September 2024 added Jornay PM, a key ADHD growth driver, and expanded its commercial infrastructure. The company also announced a $150 million share repurchase program through December 2026, following a $25 million accelerated repurchase in July 2025. Additionally, the FDA granted pediatric exclusivity for Nucynta in June 2024, extending market protection until 2027 and addressing long-term competitive risks. These moves underscore strategic focus on portfolio diversification and shareholder value.

Conclusion

Collegium’s Q3 2025 results and guidance raise highlight its ability to capitalize on therapeutic demand and operational leverage. With a strengthened balance sheet, expanded product portfolio, and favorable regulatory protections, the company is well-positioned for continued growth in 2026. Investors may benefit from monitoring execution on commercial expansion and business development initiatives.